Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03244956
Title Efficacy of MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid Cancer (MERAIODE)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Gustave Roussy, Cancer Campus, Grand Paris
Indications

thyroid gland papillary carcinoma

thyroid gland follicular carcinoma

Therapies

Trametinib

Dabrafenib + Trametinib

Age Groups: senior | adult
Covered Countries

Additional content available in CKB BOOST